{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1571135650692415744.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"NAID","@value":"10024013505"}}],"dc:title":[{"@language":"en","@value":"Clinical experience with gefitinib : an update"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1581135650692415744","@type":"Researcher","foaf:name":[{"@language":"en","@value":"CAPPUZZO F"}]}],"publication":{"prism:publicationName":[{"@language":"en","@value":"Crit Rev Oncol Hematol"}],"prism:publicationDate":"2006","prism:volume":"58","prism:startingPage":"31","prism:endingPage":"45"},"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1573668925482818304","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer"}]}],"dataSourceIdentifier":[{"@type":"CIA","@value":"10024013505"}]}